Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...
The Mail on MSN9h
Ulverston: GSK taskforce aims to allocate £2 million by JuneA TASKFORCE will aim to allocate £2 million to a successful project in Ulverston by June as a ‘lasting legacy’ from a pharmaceutical ...
With profit at an eight-year high, pharmaceutical May & Baker Nigeria Plc reported a 56 percent growth despite high operation ...
The development marks a significant change of guard at India's most prominent 'classic' motorcycle brand.
Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) reflecting updated views and recent competitive ...
LSE:GSK Earnings and Revenue History February 12th 2025 How Do Unusual Items Influence Profit? Importantly, our data ...
Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...
Morgan Stanley initiated coverage of GSK (GSK) with an Equal Weight rating and 1,450 GBp price target The shares trade at an inexpensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback